The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

Mer­ck con­sis­tent­ly spot­light­ed the multi­bil­lion-dol­lar sales po­ten­tial of so­tater­cept, the lead drug in Ac­celeron’s pipeline, as it ex­plained to in­vestors why it wa­gered $11.5 bil­lion to ac­quire the biotech late last year.

The phar­ma gi­ant is now one step clos­er to ful­fill­ing that po­ten­tial.

As promised, Mer­ck has un­veiled topline da­ta from the piv­otal Phase III STEL­LAR tri­al, which it said met the pri­ma­ry end­point as well as all but one of the nine sec­ondary end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER